Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.52 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.52 |
| ▸ | GABRP | O00591 | 1/20 | 0.52 |
| ▸ | GABRD | O14764 | 1/20 | 0.52 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5315508 | 0.84 | — | — | |
| SCHEMBL7038589 | 0.75 | HDAC3 (0.35) | KMT2ANPSR1HDAC3HDAC1HDAC2 | |
| SCHEMBL23051809 | 0.75 | TSHR (0.60) | LMNATHRBKMT2ATSHRHDAC11 | |
| SCHEMBL7356376 | 0.75 | ALDH1A1 (0.53) | KMT2ANPSR1MEN1ALDH1A1 | |
| SCHEMBL959285 | 0.74 | — | — | |
| SCHEMBL2812339 | 0.74 | — | — | |
| SCHEMBL14895816 | 0.73 | CYP2D6 (0.48) | LMNATHRBBLMKMT2ANPSR1 | |
| SCHEMBL1285375 | 0.73 | HSP90AA1 (0.58) | KMT2ATSHRHDAC11MEN1ALDH1A1 | |
| SCHEMBL8779189 | 0.73 | — | — | |
| SCHEMBL2527724 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265921-A1 | CHARGED COMPOUNDS COMPRISING A NUCLEIC ACID BINDING MOIETY AND USES THEREFOR | Genesoft, Inc. (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001074898-A2 | CHARGED COMPOUNDS COMPRISING A NUCLEIC ACID BINDING MOIETY AND USES THEREFOR | GENESOFT, INC. (US) | 2001-10-11 | — | — | WO | claimed |
| US-7301037-B2 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1265921-B1 | CHARGED COMPOUNDS COMPRISING A NUCLEIC ACID BINDING MOIETY AND USES THEREFOR | GENESOFT INC (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20070105135-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-7078536-B2 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20030211508-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT, INC. | 2003-11-13 | — | — | US | disclosed |
| US-6555693-B2 | Compounds that affect the expression of genes essential for the proliferation of the pathogen; promoters or gene expression inhibition; binding to double-stranded DNA; fungicides; bactericides; viricides | GENESOFT, INC. | 2003-04-29 | — | — | US | disclosed |
| EP-1265921-A1 | CHARGED COMPOUNDS COMPRISING A NUCLEIC ACID BINDING MOIETY AND USES THEREFOR | Genesoft, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020065227-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT PHARMACEUTICALS, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002034295-A1 | SYNTHETIC REGULATORY COMPOUNDS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2002-05-02 | — | — | WO | disclosed |
| WO-2001074898-A2 | CHARGED COMPOUNDS COMPRISING A NUCLEIC ACID BINDING MOIETY AND USES THEREFOR | GENESOFT, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211508-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | POLRMT, PCNA, SARS1 | LMNA 255/4885THRB 3881/4885BLM 1227/4885 |
| US-20070105135-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | POLRMT, PCNA, SARS1 | LMNA 255/4885THRB 3881/4885BLM 1227/4885 |
| US-20020065227-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | POLRMT, PCNA, SARS1 | LMNA 255/4885THRB 3881/4885BLM 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.